Achieve Life Sciences Inc (ACHV)
4.64
-0.09
(-1.90%)
USD |
NASDAQ |
Jun 25, 16:00
4.64
0.00 (0.00%)
After-Hours: 20:00
Achieve Life Sciences Research and Development Expense (Quarterly): 2.799M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.799M |
| December 31, 2023 | 2.114M |
| September 30, 2023 | 3.581M |
| June 30, 2023 | 4.585M |
| March 31, 2023 | 5.534M |
| December 31, 2022 | 8.614M |
| September 30, 2022 | 9.869M |
| June 30, 2022 | 7.207M |
| March 31, 2022 | 4.388M |
| December 31, 2021 | 4.506M |
| September 30, 2021 | 4.591M |
| June 30, 2021 | 9.227M |
| March 31, 2021 | 5.642M |
| December 31, 2020 | 2.347M |
| September 30, 2020 | 1.891M |
| June 30, 2020 | 1.103M |
| March 31, 2020 | 1.541M |
| December 31, 2019 | 1.763M |
| September 30, 2019 | 1.824M |
| June 30, 2019 | 2.032M |
| March 31, 2019 | 4.055M |
| December 31, 2018 | 2.081M |
| September 30, 2018 | 1.541M |
| June 30, 2018 | 1.045M |
| March 31, 2018 | 1.201M |
| Date | Value |
|---|---|
| December 31, 2017 | 2.153M |
| September 30, 2017 | 0.825M |
| June 30, 2017 | 0.062M |
| March 31, 2017 | 0.061M |
| December 31, 2016 | -12.80M |
| September 30, 2016 | 3.782M |
| June 30, 2016 | 4.662M |
| March 31, 2016 | 4.642M |
| December 31, 2015 | 6.588M |
| September 30, 2015 | 8.303M |
| June 30, 2015 | 6.545M |
| March 31, 2015 | 3.673M |
| December 31, 2014 | 9.852M |
| September 30, 2014 | 9.586M |
| June 30, 2014 | 9.883M |
| March 31, 2014 | 16.90M |
| December 31, 2013 | 13.20M |
| September 30, 2013 | 18.00M |
| June 30, 2013 | 13.26M |
| March 31, 2013 | 10.86M |
| December 31, 2012 | 15.64M |
| September 30, 2012 | 12.90M |
| June 30, 2012 | 6.326M |
| March 31, 2012 | 5.082M |
| December 31, 2011 | 7.477M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.103M
Minimum
Jun 2020
9.869M
Maximum
Sep 2022
4.258M
Average
3.984M
Median
Research and Development Expense (Quarterly) Benchmarks
| Accelerate Diagnostics Inc | 5.173M |
| Atossa Therapeutics Inc | 3.748M |
| ENDRA Life Sciences Inc | 1.042M |
| Perspective Therapeutics Inc | 7.452M |
| Electromed Inc | 0.167M |